> top > projects > sentences > docs > PubMed:21211797 > annotations
sentences Home  

PubMed:21211797 JSONTXT 12 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-162 Sentence denotes Mannose binding lectin 2 haplotypes do not affect the progression of coronary atherosclerosis in men with proven coronary artery disease treated with pravastatin.
T1 0-162 Sentence denotes Mannose binding lectin 2 haplotypes do not affect the progression of coronary atherosclerosis in men with proven coronary artery disease treated with pravastatin.
TextSentencer_T2 163-173 Sentence denotes OBJECTIVE:
T2 163-173 Sentence denotes OBJECTIVE:
TextSentencer_T3 174-259 Sentence denotes Mannose binding lectin (MBL) is one of the three initiators of complement activation.
T3 174-259 Sentence denotes Mannose binding lectin (MBL) is one of the three initiators of complement activation.
TextSentencer_T4 260-364 Sentence denotes Polymorphisms of the MBL2 gene and its promoter, and especially haplotypes, determine MBL plasma levels.
T4 260-364 Sentence denotes Polymorphisms of the MBL2 gene and its promoter, and especially haplotypes, determine MBL plasma levels.
TextSentencer_T5 365-440 Sentence denotes MBL deficiency has been associated with the development of atherosclerosis.
T5 365-440 Sentence denotes MBL deficiency has been associated with the development of atherosclerosis.
TextSentencer_T6 441-652 Sentence denotes We evaluated whether the rate of angiographic progression of coronary atherosclerosis during pravastatin treatment was associated with MBL2 haplotypes in REGRESS, a placebo-controlled 2 years intervention study.
T6 441-652 Sentence denotes We evaluated whether the rate of angiographic progression of coronary atherosclerosis during pravastatin treatment was associated with MBL2 haplotypes in REGRESS, a placebo-controlled 2 years intervention study.
TextSentencer_T7 653-661 Sentence denotes METHODS:
T7 653-661 Sentence denotes METHODS:
TextSentencer_T8 662-843 Sentence denotes Three polymorphic sites in exon 1 (rs1800450, rs1800451 and rs5030737) of the MBL2 gene and 2 sites (rs7096206 and rs11003125) in the promoter region were genotyped in 398 subjects.
T8 662-843 Sentence denotes Three polymorphic sites in exon 1 (rs1800450, rs1800451 and rs5030737) of the MBL2 gene and 2 sites (rs7096206 and rs11003125) in the promoter region were genotyped in 398 subjects.
TextSentencer_T9 844-921 Sentence denotes Genotyping was performed using Applied Biosystems® TaqMan® Genotyping Assays.
T9 844-921 Sentence denotes Genotyping was performed using Applied Biosystems® TaqMan® Genotyping Assays.
TextSentencer_T10 922-998 Sentence denotes We divided the group in high, intermediate and low MBL2 secretor haplotypes.
T10 922-998 Sentence denotes We divided the group in high, intermediate and low MBL2 secretor haplotypes.
TextSentencer_T11 999-1047 Sentence denotes Quantitative coronary angiography was performed.
T11 999-1047 Sentence denotes Quantitative coronary angiography was performed.
TextSentencer_T12 1048-1179 Sentence denotes Endpoints were mean segment diameter (MSD) and minimum obstruction diameter (MOD) established by quantitative coronary angiography.
T12 1048-1179 Sentence denotes Endpoints were mean segment diameter (MSD) and minimum obstruction diameter (MOD) established by quantitative coronary angiography.
TextSentencer_T13 1180-1188 Sentence denotes RESULTS:
T13 1180-1188 Sentence denotes RESULTS:
TextSentencer_T14 1189-1340 Sentence denotes At inclusion, 50.1, 31.7 and 17.6% of the patients in the REGRESS cohort carried the high, intermediate and low MBL2 secretor haplotypes, respectively.
T14 1189-1340 Sentence denotes At inclusion, 50.1, 31.7 and 17.6% of the patients in the REGRESS cohort carried the high, intermediate and low MBL2 secretor haplotypes, respectively.
TextSentencer_T15 1341-1400 Sentence denotes In 0.6% of the patients, the haplotype was not informative.
T15 1341-1400 Sentence denotes In 0.6% of the patients, the haplotype was not informative.
TextSentencer_T16 1401-1527 Sentence denotes There were no baseline differences between the MBL2 haplotypes for age, BMI, lipid levels, leukocyte counts, CRP, MSD and MOD.
T16 1401-1527 Sentence denotes There were no baseline differences between the MBL2 haplotypes for age, BMI, lipid levels, leukocyte counts, CRP, MSD and MOD.
TextSentencer_T17 1528-1640 Sentence denotes The intermediate MBL2 placebo group showed the greatest increase in MSD compared to the low MBL2 group (P=0.03).
T17 1528-1640 Sentence denotes The intermediate MBL2 placebo group showed the greatest increase in MSD compared to the low MBL2 group (P=0.03).
TextSentencer_T18 1641-1687 Sentence denotes No difference was found for the change in MOD.
T18 1641-1687 Sentence denotes No difference was found for the change in MOD.
TextSentencer_T19 1688-1782 Sentence denotes No significant interaction between MBL2 haplotype groups and pravastatin therapy was observed.
T19 1688-1782 Sentence denotes No significant interaction between MBL2 haplotype groups and pravastatin therapy was observed.
TextSentencer_T20 1783-1794 Sentence denotes CONCLUSION:
T20 1783-1794 Sentence denotes CONCLUSION:
TextSentencer_T21 1795-2010 Sentence denotes In men with proven coronary artery disease, MBL2 secretor haplotypes are not associated to the rate of progression of coronary sclerosis nor does pravastatin treatment influence progression based on MBL2 haplotypes.
T21 1795-2010 Sentence denotes In men with proven coronary artery disease, MBL2 secretor haplotypes are not associated to the rate of progression of coronary sclerosis nor does pravastatin treatment influence progression based on MBL2 haplotypes.